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Diabetes mellitus (DM) is most devastating, chronic, common
non-communicable disease (NCD) and has become a serious
problem globally. The number of the diabetic population
around the globe is continuously increasing with a current esti-
mation of 371 million cases in 2012 and it is expected to reach
552 million by 2030 (IDF diabetes atlas, 2012). It is also esti-
mated that 5% of all deaths in the world are caused by diabe-
tes and the number is rapidly increasing. Among two general
types of diabetes, type 1 diabetes (TIDM) is characterized by
immune complex mediated attack on insulin producing b cells
of the pancreas (Atkinson and Eisenbarth, 2001). Type 2 dia-
betes (T2DM) arises due to either insufﬁcient insulin synthesis
or the body’s inability to respond secreted insulin and leading
to glucose build-up in the blood (DeFronzo, 1997). The
impairment in glucose control leads to both micro and macro
vascular complications that often result in the other clinical
conditions associated with diabetes.
The chemical methods of treatment for diabetes do not ad-
dress the causes of the disease and have side effects. Thus,
there is an obvious search for the suitable alternative treatment
methods. The current cellular based therapeutic method for
the treatment of diabetes is focused on the transplantation of
either the pancreas or islet-cells to reconstitute the insulin-
secreting functional b cells. However, this technique is ham-
pered by a shortage of donor organs. All these issues pavedFigure 1 Self renewal and differentthe way to explore the research possibilities of generating
pancreatic b cells from stem cells. The unique regenerative
properties of stem cells could be a vital tool which can be
exploited in the treatment of diabetes. Developing a renewable
source of islets with stem cells would circumvent the
current supply/demand issues in islet transplantation and
provide patients with a long-term source of insulin-producing
b-cells. Thus, stem cell investigation has become the centre
of attraction for diabetic treatment (Mccall et al., 2009). This
article reviews the progress of stem cell research made in the
ﬁeld of diabetic treatment and practical hurdles associated
with it.
2. Stem cells and their therapeutic potential
The stem cells are more gifted and are responsible for the for-
mation of different types of cells during the early embryonic
life and the later growth of the organism. Stem cells possess
an exceptional quality to replenish itself and to produce any
specialized cell types under appropriate microenvironment. A
rapidly dividing stem cell produces two new cells, each having
two choices depending upon the requirement of the organism.
Thus, a newly produced cell either may remain as a stem cell or
it may undergo further differentiation to become a more spe-
cialized cell with speciﬁc function. The stem cells have the po-
tential to become any type of specialized cell such as a
myocyte, blood cell, hepatocyte and brain cell (Fig. 1). Theiation potential of the stem cells.
Figure 2 Pluripotent stem cell forms the cells of all there germ layers.
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marrow and gut to repair and replace the damaged tissues.
However, in some other organs such as in the heart and
pancreas, the stem cells remain as a resident cell and undergo
division only under speciﬁc requirement.
The stem cells can be classiﬁed in many ways based on the
origin, potential, source and method of derivation etc. In gen-
eral, based on the source, stem cells can be broadly classiﬁed
into two types as embryonic stem cells (ESCs) and adult stem
cells. The ESCs are obtained from the inner cell mass of a 4–5-
day old embryo (blastocyst). Nearly, three decades ago, the
researchers isolated the ESCs from the mouse embryos (Evans
and Kaufman 1981; Martin 1981). Later, Thomson et al.
(1998) were successful enough to isolate and continuously cul-
ture the ESCs of a human blastocyst (Thomson et al., 1998).
The ESC are capable of forming the cells of all three germ lay-
ers and they are termed as pluripotent stem cells (Fig. 2). The
adult stem cells are very rare stem cells found in almost all ma-
jor organs and are referred as multipotent cells due to their
limited ability to differentiate.
Scientists around the globe are making a considerable effort
to make use of different type stem cells for the treatment of
various medical conditions (Liu et al., 2013). Although as yet
there have been no approved treatments using ESCs, adult
stem cell use has become fairly common in medical practice.
Bone marrow transplantation employs hematopoietic stem
cells (HSCs) taken from donor marrow to successfully treat
leukaemia and other haematological malignancies. This suc-
cess has led researchers to explore other uses, including the
treatment of stroke (Haas et al., 2005), blindness (Adler,
2008) and even myocardial infarctions (Meyer et al., 2007).
The stem cell based therapy for diabetes, aims to replace the
diseased or lost cells of the pancreas by using pluripotent or
multipotent stem cells. The research to date has explored the
potential of different type of stem cells (induced pluripotent
stem cells (iPSCs), embryonic stem cells (ESCs) and adult stemcells) by various approaches to generate surrogate b cells or to
restore b-cell function (Fig. 3).3. Adult stem cells and diabetes
3.1. Pancreatic stem cells
The technological advancements over a decade enabled the sci-
entiﬁc community to derive stem cells from various types of tis-
sue sources including bone marrow, umbilical cord blood,
adipose tissue, skin, periosteum, dental pulp etc. The pancreas
is an organ of ﬁrst choice to be looking for the potential stem
cells. Animal studies have shown that the availability of small
amounts of pancreatic tissue would restore the maximum pan-
creatic b-cell mass (Bonner-Weir et al., 1993). This is due to the
replication of differentiated b-cells of pancreatic ducts and
dedifferentiation of these cells to pluripotent cells that in turn
produce more b-cells. Further investigation revealed that this
population of ductal cells could, in vitro, be cultivated and di-
rected to form insulin producing clusters (Bonner-Weir et al.,
2000; Gao et al., 2003). Seaberg et al. (2004) developed a clonal
population of adult pancreatic precursor cells from ductal cells
that can produce both C-peptide and insulin. Studies have
shown that the islets of both rodent and human contains mul-
tipotent stem cells (Eberhardt et al., 2006; Zulewski et al.,
2001). Earlier, many researchers raised their speculation about
the existence of pancreatic adult stem, despite the progress and
promise of pancreatic stem cells (Dor et al., 2004). Later, Xu
et al. (2008) have provided a strong evidence for the existence
of multipotent progenitor cells in the pancreatic ducts of mice
that can give rise to new b-cells (Xu et al., 2008). These studies
and other reports conclusively prove two facts, ﬁrst the exis-
tence of pancreatic stem cell and second the b-cells can be
formed from non-b-cells. However, further research needs to
focus on ﬁnding and activating pancreatic stem cells in diabetic
Figure 3 Different types of stem cell resources with a potential to be developed into insulin secreting cells.
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are required to develop suitable methods to address the issue
of isolation and ex vivo expansion of these stem cells for trans-
plantation (Michael et al., 2010).
3.2. Haemopoietic progenitor cells
The adult stem cells of the haemopoietic system, like HSCs and
mesenchymal stem cells (MSCs) are having the ability to trans-
differentiate into a number of other cell lineages, including the
liver, brain, lung and even gastrointestinal tract cells (Brazel-
ton et al., 2000; Jiang et al., 2002; Krause et al., 2001; Lagasse
et al., 2000). This multipotent differentiation of haemapoietic
progenitors was explored in greater detail by various groups
of researchers to replenish the b-cell population in T1DM.
The mouse bone marrow cells were differentiated into func-
tionally competent b-cells in an in vivo experiment (Ianus et al.,
2003). Similar experiments with mice showed that bone mar-
row cells can be targeted to the pancreas and that hyperglyca-
emia can be reversed (Hess et al., 2003). Studies carried out
with autologous HSCs showed improvement in both type 1
(Couri et al., 2009) and type 2 diabetes mellitus (Estrada
et al., 2008). These trials provide promising results for the
use of autologous HSCs in the treatment of diabetes.
3.3. Other adult stem cells
The liver and small intestine are extensively studied as poten-
tial sources of pancreatic b-cells. These organs have an edge
over others as they are derived from endoderm along with
the pancreas. Different research groups around the nations
have successfully transdifferentiated rodent hepatic cells intoinsulin-producing cells via multiple genetic approaches (Ber
et al., 2003; Kim et al., 2007; Sapir et al., 2005; Yang et al.,
2002). Regardless of the method used, amelioration of hyper-
glycaemia was achieved by these cells in the mouse models.
This created hope among the researchers to search for extra-
pancreatic sources of insulin (Zalzman et al., 2003).
Many other stem cell resources have been explored for the
production of insulin secreting b cells and different degrees of
success have been achieved with them. The resources include
the stem cells of the small intestine (Suzuki et al., 2003; Yos-
hida et al., 2002), salivary glands (Okumura et al., 2003) and
adipose tissue (Timper et al., 2006). However, many experi-
mental results and the embryological proximity of the liver
to pancreas suggest that this organ could be an ideal non-pan-
creatic stem cell source of b-cells that can be utilized the cure of
diabetes. In the years to come, the hepatic production of insu-
lin has the potential to become a viable source for b-cell
replacement. This is possible not before addressing the practi-
cal hurdles associated with these cell lines, culture conditions,
complete differentiation, and islet structure formation etc.
(Michael et al., 2010).
4. ESCs and diabetes
The pluripotent nature of the ESCs has been hailed for long by
the researchers and these cells are explored for their use in a
number of medical conditions, including diabetes (Trounson,
2013). ESCs are viewed as an excellent resource for the gener-
ation of insulin secreting islet cells through the established
developmental and differentiation pathways. Theoretically it
is possible, despite the difﬁculties, that ESCs could be directed
to differentiate into pancreatic islet cells and these cells could
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icit could be circumvented.
Over a decade ago, pancreatic islet cells were produced from
mouse ESCs. The researchers developed insulin-secreting
clones from a genetically engineered and drug-selected mouse
ESC line. These cells were transplanted into diabetic mice
and resulted in the amelioration of hyperglycaemia for few
months (Soria et al., 2000). A number of other groups have also
utilized both mouse (Blyszczuk et al., 2004; Hori et al., 2002;
Kahan et al., 2003; Lumelsky et al., 2001; Leon-Quinto et al.,
2004) and human (Assady et al., 2001; Segev et al., 2004) ESCs
for their studies and have reported the different degree of suc-
cess in producing islets. All these efforts have come across dif-
ferent issues that include ﬁnal cell homogeneity (Lumelsky
et al., 2001), immaturity of the differentiated cells (Segev
et al., 2004), low numbers of insulin-producing cells (Hori
et al., 2005) and a poor insulin response when the cells were ex-
posed to glucose (Assady et al., 2001; Miyazaki et al., 2004). To
add this, few groups of researchers also argued that these cells
were not actually insulin producing cells as they could not pro-
duce C-peptide and intracellular insulin once the cells were cul-
tured in insulin-free medium (Hansson et al., 2004; Rajagopal
et al., 2003; Sipione et al., 2004). Despite the ray of hope, it
was certainly proving difﬁcult to create reliable insulin-produc-
ing b-cell phenotype from ESCs. All these issues collectively
forced the researchers to rethink their differentiation strategies
and Kubo et al. (2004) developed a recipe to convert mouse
ESCs into deﬁnitive endoderm (Kubo et al., 2004). This proto-
col was redeﬁned by D’Amour et al. to produce a near 100%
pure deﬁnitive endodermal cell population (D’Amour et al.,
2005). The same group had demonstrated the production of
pancreatic endocrine hormone- producing cells that contained
both insulin and C-peptide by a ﬁve stage in vitro differentiation
process (D’Amour et al., 2006). Through these inventions, these
researchers were able to produce insulin from these cells in the
range of human islets; but could not establish the insulin re-
sponse to glucose. Later, this response was achieved by Kroon
et al.(2008) as the hyperglycaemic responsiveness is a crucial
characteristic that is needed for any potential cellular diabetic
therapy. This group transplanted their unique differentiated
cells that resemble 6–9-week-old embryo into the immunodeﬁ-
cient mice and showed that the insulin release was glucose-
dependent. This allowed the cells to both recover mice from
STZ (streptozotocin)-induced diabetes as well as to prevent it
(Kroon et al., 2008). These discoveries may lead the way for
ESCs to become a strong candidate for cellular replacement
therapy in T1DM in near future.5. Induced pluripotent stem cells and diabetes
The production of pluripotent stem cells from non pluripotent
resource is referred as induced pluripotency. Somatic cells canTable 1 Primary concerns associated with stem cells in the treatme
Forefront issue
1 Safe administr
2 Transplantatio
3 Side eﬀects and
4 Scale up poten
5 Ethical issues cbe reprogrammed to produce pluripotent stem cell under spe-
ciﬁc conditions and such cell is known as induced pluripotent
stem cell (iPSC). Induced pluripotency is achieved by directed
expression of speciﬁc transcription factors (Yamanaka, 2008).
The induced pluripotent stem cells (iPSCs) exhibit high telome-
rase activity similar to that of ESCs and possess hypomethylat-
ed gene promoters (Maherali and Hochedlinger, 2008;
Takahashi et al., 2007). These iPSCs are preferred choices of
cell based therapy for diabetes management as they can be pa-
tient speciﬁc and eliminate the possibility of likelihood rejec-
tion. The ﬁbroblast cells are induced to produce iPSCs and
these cells are later converted to pancreatic beta like cells by
a three-stage differentiation process. The transplantation of
ﬁbroblast derived beta like cells in diabetic mouse model was
effective in controlling hyperglycaemia for long term (Alipio
et al., 2010). Zhang and colleagues have shown that the human
ESCs and iPSCs were differentiated into mature pancreatic
cells that were capable of secreting both insulin and C-peptide
(Zhang et al., 2009). The lentiviral transfection method is uti-
lized to reprogramme the adult pancreatic beta-cells into iPS-
Cs. The produced cells were capable of differentiating into
cells of all three germ layers (Maehr et al., 2009; Stadtfeld
et al., 2008). The ﬁbroblastic cells of type 1 diabetic patient
were induced to produce pluripotent stem cells by the lentiviral
transfection method and the produced cells are identiﬁed as
insulin secreting cells (Maehr et al., 2009). The above men-
tioned research innovations and recent progress in the ﬁeld
of induced pluripotency would allow the usage patient-speciﬁc
iPSCs for cell based therapies in diabetes. However, the safe
usage of iPSCs for diabetes management must be ensured as
these cells exhibit irregular behaviour and signiﬁcant varia-
tions in reprogramming (Lister et al., 2011).
6. Hurdles in the progress
Despite the valiant strides made in the ﬁeld of stem cell biology
over a decade, the usage of stem cells in diabetes treatment is
still in its primitive stage. The effective and full-ﬂedged usage
of stem cells relies upon how well the associated issues and
hurdles are resolved. The stem cell based cure of diabetes will
become reality only when all the difﬁculties are properly iden-
tiﬁed and effectively addressed. The progress of stem cell re-
search has been hampered by both technological as well as
ethical issues. The predominant concerns associated with the
development of a potential source of stem cells for the treat-
ment of diabetes have been listed in Table 1.
6.1. Safety aspects
The ability to form teratomas and the potential risk of malig-
nancy are the key features associated with the usage of ESCs
(Leon-Quinto et al., 2004). Thus, there should be a rigorousnt of diabetes.
s associated with the stem cell usage for diabetic treatment
ation and potential risk of teratoma formation.
n complications and acclimatization in the tissue microenvironment.
risk factors associated with immunosuppression.
tial of stem cells.
oncerned with the use of ESCs.
338 S. Sheik Abdulazeeztesting and screening for potential side effects before using it in
clinical trials and for treatment in human population.
6.2. Transplantation issues
The autoimmune rejection is a major issue during transplanta-
tion and that requires a stable and appropriate immunosup-
pression regime. Current transplantation protocols need to
be stabilized with the standard testing module. Stem cell trans-
plantation requires a number of studies to discuss the issues
associated with the transplanted cell survival, stability and
durability in the new microenvironment with appropriate vas-
cular and neural support.
6.3. Scale up issues
Once the appropriate developmental procedures are optimized
then comes the scale up issues. The quantity of cells needs to
meet the demands for further research including clinical trials.
Thus it requires efﬁcient techniques to maximize the yield by
adjusting the culture requirements. To maintain the balance
between the demand and usage, the scale-up potential of stem
cells needs further exploration to provide an excess of trans-
planted cellular reserves.
6.4. Ethical issues
Due to the nature of its origin, the ESCs are the hot target for
the ethicists. Generally, ESCs are usually derived from unused
and/or unfertilized embryos at in vitro fertilization clinics.
These ESCs need to be procured from the donor on the basis
of informed consent before using them for any clinical study.
However, in most of the cases the cells from the embryo are
obtained by destroying the embryo and that rises the question
about the origin of life and ethical rights to destroy the em-
bryo. The answer will lead into the never ending debate and
it is always advisable to follow the set of rules that are laid
by the governing bodies around the globe based on the senti-
ments and beliefs of people from that particular geographical
location. The adult stem cells are preferred over their embry-
onic counterpart as there is no much controversy about the
usage of adult stem cells. However it is always safer to adopt
the policy of transparency regarding the derivation and usage
of stem cells whatever may be the source of their origin. The
recent technological advancements in the ﬁeld of induced plu-
ripotent stem cell research allow the usage of persons own stem
cells for different purposes (Holm, 2008; Yu et al., 2007). In
such cases, adult cells are reprogrammed to the pluripotent
state and subsequently differentiated into functional b-cells.
This technique may eventually solve the issues associated with
the embryonic stem cells but adds further safety burden prob-
ably to be solved in the near future.7. Conclusions
Over a decade of research clearly suggests that insulin produc-
ing cells may be derived from stem cells. However there is a
need for further development of methods for differentiation
and selection of completely functional b cells. The regeneration
of b cells is possible by controlling the regulation of variousfactors. Exploration of these b cell regulation pathways would
be logical strides towards the curative efforts in diabetes treat-
ment. Despite the achievements and progress with the stem
cells, the key issues like safety concerns, teretoma formation,
transplantation issues and autoimmune response, and ethical
dilemmas of ESCs limit their further exploration in clinical tri-
als. Similarly, the issues associated with the scale up produc-
tion, hamper the exploration of adult stem cells and iPSCs
to be used as a choice of therapeutic resources. The scientiﬁc
effort of a past decade enabled us to produce insulin secreting
cells and the future years may come up with the solutions to
use stem cells as a therapeutic agent to cure diabetes.
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